Core One Labs Inc. (CLABF)
| Market Cap | 47.00 -100.0% |
| Revenue (ttm) | 338.91K -18.7% |
| Net Income | -11.81M |
| EPS | -0.36 |
| Shares Out | 47.10M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 71,759 |
| Open | 0.0181 |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | 0.57 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 28, 2026 |
About Core One Labs
Core One Labs Inc. operates as a psychedelic research and development company. The company focuses on providing psychedelic medicines to novel delivery systems and psychedelic assisted psychotherapy; and intends to further develop and apply the technology to psychedelic compounds, such as psilocybin. It also provides natural health products; news dissemination services; financing services; and operates medical clinics, as well as engages in micro cultivation. The company was formerly known as Lifestyle Delivery Systems Inc. and changed its name... [Read more]
News
CSE Bulletin: Delist - Core One Labs Inc. (COOL)
Toronto, Ontario--(Newsfile Corp. - Le 19 septembre/September 2025) - The common shares of Core One Labs Inc. will be delisted from the CSE at market close today, September 19, 2025. Core One Labs Inc...
Core One Enters into Loan Agreement with Right Season Investments
VANCOUVER, BC / ACCESSWIRE / July 8, 2024 / Core One Labs Inc. (CSE:COOL)(OTCQB:CLABF)(Frankfurt:LD6, WKN: A3CSSU) (the "Company" or "Core One"), is pleased to announce that it has entered into a loan...
Core One Labs Inc. Announces Initial Agreement for Potential Sale of Proprietary Biosynthetic Psilocybin, Facilitating Entry into the International Market
VANCOUVER, BC / ACCESSWIRE / December 8, 2023 / Core One Labs Inc. (CSE:COOL)(OTCQB:CLABF)(Frankfurt:LD6) (WKN:A3CSSU) (the "Company" or "Core One") is pleased to announce the signing of an Initial Ag...
Core One Labs' Akome Reveals Impressive Results for its Psychedelic Bio-Compounds Designed to Target Alzheimer's and Parkinson's, Showing Potential to Outperform Current Treatment Methods
VANCOUVER, BC / ACCESSWIRE / December 1, 2023 / Core One Labs Inc. ("Core One" or the "Company") (CNSX:COOL)(OTCQB:CLABF)(Frankfurt:LD6) (WKN: A3CSSU), an emerging leader in the field of neuroscience ...
Core One's Akome Reveals Groundbreaking Positive Results from its Second Round of Stage 1 Animal Model Studies for Bio-Compounds Targeting Alzheimer's and Parkinson's Disease
VANCOUVER, BC / ACCESSWIRE / August 4, 2023 / Core One Labs Inc. (CSE:COOL) (OTCQB:CLABF) (Frankfurt:LD6, WKN:A3CSSU), (the "Company" or "Core One") is delighted to announce the receipt of additional ...
Core One Labs', Awakened Biosciences, Announces Groundbreaking Step Forward in Isolating and Purifying Psilocybin from Mushroom Biomass
Core One's Wholly-Owned Subsidiary has filed a patent application with the United States Patent and Trademark Office VANCOUVER, BC / ACCESSWIRE / August 1, 2023 / Core One Labs Inc. (CSE:COOL)(OTCQB:C...
Core One's Akome Receives Positive Preliminary Stage 1 Animal Model Study Results for Bio-Compound Targeting Alzheimer's and Parkinson's Disease
VANCOUVER, BC / ACCESSWIRE / July 28, 2023 / Core One Labs Inc. (CSE:COOL)(OTCQB:CLABF)(Frankfurt:LD6) (WKN:A3CSSU) (the "Company" or "Core One"), is excited to share positive results from its first r...
Core One Labs Enters into Letter of Intent for First Sale of Its Psychedelic Compounds
VANCOUVER, BC / ACCESSWIRE / July 21, 2023 / Core One Labs Inc. (CSE:COOL)(OTCQB:CLABF)(Frankfurt:LD6) (WKN: A3CSSU) (the "Company" or "Core One") is pleased to announce that its wholly-owned subsidia...
Core One's Vocan Biotechnologies Incorporates New Bioreactor Equipment into Production Process Significantly Increasing Throughput of Proprietary Biosynthetic Psilocybin
VANCOUVER, BC / ACCESSWIRE / July 11, 2023 / Core One Labs Inc. (CSE:COOL), (OTCQB:CLABF), (Frankfurt:LD6, WKN:A3CSSU) (the "Company") is pleased to announce that its wholly-owned subsidiary Vocan Bio...
Core One's Vocan Files International Patent for its Breakthrough Proprietary Biosynthetic Psilocybin Production Method
VANCOUVER, BC / ACCESSWIRE / July 7, 2023 / Core One Labs Inc. (CSE:COOL), (OTCQB:CLABF), (Frankfurt:LD6), (WKN: A3CSSU) (the "Company" or "Core One") is pleased to announce that its wholly owned subs...
Core One in Talks with Multiple Companies to Supply Psilocybin
VANCOUVER, BC / ACCESSWIRE / May 5, 2023 / Core One Labs Inc. (CSE:COOL)(OTCQB:CLABF)(Frankfurt:LD6), (WKN:A3CSSU) (the "Company" or "Core One") is pleased to announce that it is in discussions with s...
Core One Labs' GMP Drug Takes Further Steps Toward Commercialization: Initiating Development of Psychedelic Prodrugs with Long-established Compounding Pharmacy
VANCOUVER, BC / ACCESSWIRE / May 1, 2023 / Core One Labs Inc. (CSE:COOL)(OTCQB:CLABF)(Frankfurt:LD6)(WKN:A3CSSU) (the "Company" or "Core One") is pleased to announce that its wholly-owned subsidiaries...
Core One's Awakened Completes Successful Synthetic Production of Psilocin in its GMP Certified Manufacturing Facility
VANCOUVER, BC / ACCESSWIRE / April 21, 2023 / Core One Labs Inc. (CSE:COOL)(OTCQB:CLABF)(Frankfurt:LD6, WKN:A3CSSU) (the "Company" or "Core One") is pleased to announce that its wholly-owned subsidiar...
Core One Labs' Akome Signs Contract with University of Barcelona: Initiating Animal Model Studies on Psychedelics Drug Development to Combat a Variety of Neurological Diseases
VANCOUVER, BC / ACCESSWIRE / January 24, 2023 / Core One Labs Inc. (CSE:COOL)(OTCQB:CLABF)(Frankfurt:LD6)(WKN: A3CSSU) (the "Company" or "Core One"), in follow-up to its press release dated September ...
Core One Labs' Acquires GMP Drug Inc.: Positioning Itself as a Full Cycle Psychedelics Supply Chain Solution for Clinicians, Researchers and Other Drug Developers
VANCOUVER, BC / ACCESSWIRE / January 13, 2023 / Core One Labs Inc. (CSE:COOL)(OTCQB:CLABF)(Frankfurt:LD6)(WKN: A3CSSU) (the "Company" or "Core One"), is pleased to announce that it has acquired (the "...
Core One Labs' Prepares for Commercial Production of API-Grade Psilocybin; Plans Initial Production Run at GMP Facility in January
VANCOUVER, BC / ACCESSWIRE / November 18, 2022 / Core One Labs Inc. (CSE:COOL), (OTCQB:CLABF), (Frankfurt:LD6, WKN:A3CSSU) (the "Company" or "Core One") is pleased to announce the initial production r...
Core One Labs Takes Next Steps to Prepare for Potential Takeover Opportunities
VANCOUVER, BC / ACCESSWIRE / October 21, 2022 / Core One Labs Inc. (CSE:COOL), (OTCQB:CLABF), (Frankfurt:LD6, WKN:A3CSSU) (the "Company" or "Core One") is pleased to announce, as a follow up to the Co...
European University to Fund Core One Labs' Akome Advanced Neurogenesis Stimulation Studies
VANCOUVER, BC / ACCESSWIRE / October 14, 2022 / Core One Labs Inc. (CSE:COOL)(OTCQB:CLABF)(Frankfurt:LD6)(WKN:A3CSSU) (the "Company" or "Core One"), further to its press release dated August 18, 2022,...
Core One Labs Nearing GMP Production as Canada's Province of Alberta Announces Game Changing Legislation
VANCOUVER, BC / ACCESSWIRE / October 7, 2022 / Core One Labs Inc. (CSE:COOL)(OTCQB:CLABF)(Frankfurt:LD6)(WKN:A3CSSU) (the "Company" or "Core One"), is pleased to announce that it is nearing good manuf...
Core One Labs Announces Breakthrough with Proprietary Isolation and Purification Method of Psilocybin from Mushrooms; Prepares Patent Application
VANCOUVER, BC / ACCESSWIRE / September 30, 2022 / Core One Labs Inc. (CSE:COOL)(OTCQB:CLABF)(Frankfurt:LD6) (WKN: A3CSSU) (the "Company" or "Core One") is pleased to announce that its wholly-owned sub...
Core One Labs' Akome Move Psychedelic Drug Formulations to Next Stage of Development: Initiating Phase 2 Analysis of Therapeutic Potential
VANCOUVER, BC / ACCESSWIRE / September 16, 2022 / Core One Labs Inc. (CSE:COOL), (OTCQB:CLABF), (Frankfurt:LD6, WKN:A3CSSU) (the "Company" or "Core One") is pleased to announce that following the rece...
Core One Labs' Scientists Successfully Complete Breakthrough First Step in Producing API-Grade DMT
Second Ground Breaking Technological Advancement VANCOUVER, BC / ACCESSWIRE / September 2, 2022 / Core One Labs Inc. (CSE:COOL), (OTCQB:CLABF), (Frankfurt:LD6)(WKN:A3CSSU) (the "Company" or "Core One"...
Core One Rolls Out Commercial Sales Strategy for its Revolutionary API Grade Biosynthetic Psilocybin
VANCOUVER, BC / ACCESSWIRE / September 1, 2022 / Core One Labs Inc. (CSE:COOL), (OTCQB:CLABF), (Frankfurt:LD6)(WKN: A3CSSU) (the "Company" or "Core One") announces that it has initiated rollout of its...
Core One Labs Engages in Talks With GMP Manufacturing Partner for Commercial Scale Production of Proprietary Biosynthetic Psilocybin
VANCOUVER, BC / ACCESSWIRE / August 26, 2022 / Core One Labs Inc. (CSE:COOL)(OTCQB:CLABF)(Frankfurt:LD6)(WKN:A3CSSU) (the "Company" or "Core One"), a life sciences biotechnology research and developme...
Core One Labs' Akome Achieves Another Milestone in Development of its Psychedelic Drug Formulas and Announces Positive Results from Neuro-Pharmacokinetics Studies
VANCOUVER, BC / ACCESSWIRE / August 19, 2022 / Core One Labs Inc. (CSE:COOL), (OTCQB:CLABF), (Frankfurt:LD6, WKN:A3CSSU) (the "Company" or "Core One") is pleased to announce that its wholly owned subs...